missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ Toralizumab Chimeric Recombinant Rabbit Monoclonal Antibody (IDEC-131 (Toralizumab))
GREENER_CHOICE

Rabbit Recombinant Monoclonal Antibody

Brand:  Invitrogen™ MA548310

Product Code. 17981181

  • £464.00 / 200µg

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

Specificity: This antibody is a non agonistic antibody specifc for human CD40 ligand.

Toralizumab works by binding to interferon gamma, which prevents it from interacting with its receptors on immune cells. This blocks the downstream signaling pathways that lead to inflammation and tissue damage in autoimmune diseases. By blocking interferon gamma, toralizumab aims to reduce inflammation and prevent further tissue damage in affected individuals.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Toralizumab Chimeric
Recombinant Monoclonal
1 mg/mL
PBS with 0.02% ProClin 300
P08729
Rabbit
Protein A
RUO
3855
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Liquid
Inhibition Assays, Immunocytochemistry
IDEC-131 (Toralizumab)
Unconjugated
KRT7
IDEC 131
The original monoclonal antibody was generated by immunization with a soluble fusion protein of human gp39 (gp39-CD8).
200 μg
Primary
Human
Antibody
IgG κ
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.